Filing Flows › Macrogenics (MGNX) › R&D spending
Macrogenics (MGNX) R&D spending by quarter
Macrogenics' R&D spending was $38.8M in Q2 2026 (second quarter 2026), +11% from Q1 2026. Over the last 7 quarters it ranged from $32.7M (Q3 2025) to $40.8M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $38.8M | +11% | -5% |
| Q1 2026 | $35.0M | +3% | -12% |
| Q4 2025 | $34.0M | +4% | -13% |
| Q3 2025 | $32.7M | -20% | — |
| Q2 2025 | $40.8M | +3% | — |
| Q1 2025 | $39.7M | +2% | — |
| Q4 2024 | $38.9M | — | — |
Q2 2026 at a glance
Macrogenics, Q2 2026: revenue $32.8M (+378% year over year), operating margin -42.2%, net earnings $19.5M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Macrogenics' R&D spending?
Macrogenics' R&D spending was $38.8M in Q2 2026 (second quarter 2026), +11% from Q1 2026.
How has Macrogenics' R&D spending changed?
Over the last 7 quarters it ranged from $32.7M (Q3 2025) to $40.8M (Q2 2025).